MERCK KGAA
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1668-01-01
- Employees
- 62.9K
- Market Cap
- $84.2B
- Website
- http://www.merckgroup.com/de
Clinical Trials
718
Trial Phases
5 Phases
Drug Approvals
12
Drug Approvals
Levothyroxine Sodium Tablets
- Product Name
- 优甲乐
- Approval Number
- 国药准字J20160066
- Approval Date
- Jul 31, 2019
Levothyroxine Sodium Tablets
- Product Name
- 优甲乐
- Approval Number
- 国药准字J20160065
- Approval Date
- Jul 31, 2019
Metformin Hydrochloride Extended-release Tablets
- Product Name
- 格华止
- Approval Number
- J20171052
- Approval Date
- Sep 11, 2017
Metformin Hydrochloride Extended-release Tablets
- Product Name
- 格华止
- Approval Number
- 国药准字J20171052
- Approval Date
- Sep 11, 2017
Clinical Trials
Distribution across different clinical trial phases (444 trials with phase data)• Click on a phase to view related trials
Efficacy and Safety of Crinone Versus Combination Medication (ACCESS)
- First Posted Date
- 2019-02-28
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 172
- Registration Number
- NCT03858049
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, China
L-PZQ ODT in Schistosoma Infected Children
- Conditions
- Schistosomiasis
- Interventions
- First Posted Date
- 2019-02-19
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 288
- Registration Number
- NCT03845140
- Locations
- 🇨🇮
Universitè de Cocody, Abidjan, Côte D'Ivoire
🇰🇪Kemri Kisumu, Kisumu, Kenya
Effects of Cladribine Tablets on the PK of Microgynon®
- Conditions
- Relapsing Multiple Sclerosis (RMS)
- Interventions
- First Posted Date
- 2018-11-19
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 28
- Registration Number
- NCT03745144
- Locations
- 🇩🇪
St. Josef und St. Elisabeth Hospital gGmbH, Bochum, Germany
🇩🇪Nuvisan GmbH, Neu-Ulm, Germany
🇵🇱M.A. - LEK A.M.Maciejowscy SC., Katowice, Poland
Human Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]-Evobrutinib
- First Posted Date
- 2018-10-30
- Last Posted Date
- 2020-07-07
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 6
- Registration Number
- NCT03725072
- Locations
- 🇳🇱
PRA Health Sciences, Groningen, Netherlands
Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLC
- Conditions
- Squamous Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2018-10-24
- Last Posted Date
- 2022-06-06
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 43
- Registration Number
- NCT03717155
- Locations
- 🇭🇺
Semmelweis Egyetem - Pulmonologiai Klinika, Budapest, Hungary
🇭🇺Debreceni Egyetem - Tudogyogyaszati Klinika, Debrecen, Hungary
🇭🇺Petz Aladar Megyei Oktato Korhaz - Pulmonologiai Osztaly, Gyor, Hungary
- Prev
- 1
- 2
- 3
- 4
- 5
- 55
- Next
News
Moffitt Cancer Center Reports Promising Results for Avelumab-Radiation Combination in Leptomeningeal Disease
Researchers at Moffitt Cancer Center demonstrated that combining avelumab immunotherapy with whole brain radiotherapy showed promising safety and efficacy in treating leptomeningeal disease, a devastating cancer complication.
Drug Hunter Secures Seed Investment to Expand Knowledge Platform for Pharmaceutical R&D
Drug Hunter, a knowledge platform serving over 200 pharmaceutical R&D organizations including Eli Lilly, Biogen, and NIH, announced seed funding led by Teamworthy Ventures to accelerate drug discovery insights.
NRG Therapeutics Raises $67 Million to Advance Novel Mitochondrial-Targeting Therapy for Parkinson's and ALS
NRG Therapeutics secured £50 million ($67 million) in Series B funding to advance its lead compound NRG5051 into clinical trials for Parkinson's disease and ALS.
Merck KGaA Appoints David Weinreich as Global Head of R&D to Revitalize Healthcare Pipeline
Merck KGaA has appointed David Weinreich as Global Head of R&D and Chief Medical Officer for its Healthcare business sector, bringing over 20 years of experience and leadership in developing 15 approved drugs worldwide.
Proxygen Partners with EPFL to Advance AI-Driven Molecular Glue Degrader Discovery
Proxygen, a leader in molecular glue degrader discovery, has announced a strategic research collaboration with EPFL to integrate AI-driven computational design with high-throughput screening platforms.
Rituximab Outperforms Cladribine in Real-World Multiple Sclerosis Study
A Norwegian observational study of 285 RRMS patients found rituximab demonstrated superior disease control compared to cladribine, with only 17% showing new MRI activity versus 57% for cladribine over 4 years.
Merck KGaA Partners with Skyhawk Therapeutics in $2 Billion RNA Splicing Collaboration for Neurological Disorders
Merck KGaA, Darmstadt, Germany has entered a strategic collaboration with Skyhawk Therapeutics valued at over $2 billion to discover novel RNA-targeting small molecules for neurological disorders with high unmet medical need.
RESTEM Receives FDA Orphan Drug Designation for Stem Cell Therapy in Polymyositis Treatment
RESTEM, a clinical-stage biotech company, received FDA Orphan Drug Designation in December 2024 for its umbilical cord outer lining stem cell program targeting polymyositis and dermatomyositis.
MilliporeSigma and Washington University Strengthen 90-Year Partnership to Accelerate Life Sciences Innovation
MilliporeSigma and Washington University in St. Louis have signed a memorandum of understanding to expand their nearly century-long collaboration, focusing on joint research initiatives and technology development.
Simtra BioPharma Solutions Completes Major Facility Expansion in Germany to Meet Growing Injectable Therapeutics Demand
Simtra BioPharma Solutions has completed construction of a new 1,800 square meter production facility at its Halle, Germany campus, expanding total production area to nearly 12,000 square meters.